Navigation Links
GENova names Aaron Whiteman as CEO
Date:8/18/2009

NEW YORK, NY, Aug. 18 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

Mr. Whiteman, is a graduate of Oxford University and London School of Economics. He will provide GENova with his unique blend of exceptional sales, marketing, business and networking skills, combined with solid business management experience and the vision to marry novel products with new market opportunities. Mr. Whiteman has extensive experience in team building and negotiation. He has previously worked with companies such as Pfizer (NYSE: PFE), Amgen (Nasdaq: AMGN), Myriad Genetics (Nasdaq: MYGN), Medarex (Nasdaq: MEDX), and Biogen Idec (Nasdaq: BIIB).

Mr. Whiteman said, "I am excited to provide the executive leadership to take GENova to its next stage of growth in this crucial phase of commercializing GENova's technology in the marketplace."

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensure of novel therapeutic proteins that disrupt the advance of life-threatening cancers and infectious disease. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.At present, GENova is rapidly building its portfolio of proprietary biotechnology. GENova's target market - cancer treatments - is the largest disease market, exploding at a 20% growth rate each year. GENova's treatment niche is based on recent discoveries that indicate that most tumors are derived from a single cancer-initiating cell population which has stem cell properties (a cancer stem cell). GENova has chosen to concentrate on identification of certain cell-specific characteristics, making it possible to identify precursor cells of tumors, and then conduct a more extensive 'fingerprinting' profile that will enable the development of cell-specific anti-cancer treatments. This will result in a 'tailor made' cancer treatment strategy that is superior to existing therapies in its ability to eradicate malignant cells whilst leaving healthy tissue intact.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , ... as a tool to characterize particle size distributions in the field of geoscience ... and novel scientific findings. It describes methods of optimized and standardized sample collection, ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud ... The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in drug ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination ... and concern over nerve agents and the deadly use of chemical weapons. Many questions ... and how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... for wholesale distribution in North America, today announced it would be offering some ... company, which prides itself on crafting quality and unique baby clothing/feeding products, will ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Juan Monteverde , founder ... , a boutique securities firm headquartered at the Empire ... , announces that a class action lawsuit has been ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the ... July 23, 2015 and December 30, 2016, inclusive (the ...
(Date:2/24/2017)... YORK , Feb. 23, 2017 Report analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/24/2017)... le 24 février 2017 ITL Limited, ( ASX : ITD ... est ravie d,annoncer les excellents résultats semestriels clos le ... correspondante. Une présentation complète « Résultats et mise à jour ... ici . Faits marquants ... 2015 : 1,04 million $ ; en hausse de 104 %) ...
Breaking Medicine Technology: